A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

NCT01320085 ↗

Phase 2 Completed 183 enrolled Pfizer

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The study will assess the safety and efficacy of single-agent MEK162 in adult patients with locally advanced and unresectable or metastatic malignant cutaneous melanoma, harboring BRAFV600E or NRAS mutations.

Timeline

Start: 2011-03-24
Primary completion: 2014-01-07
Completion: 2023-02-06

Publications

Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zubel A, Dummer R. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013 Mar;14(3):249-56. doi: 10.1016/S1470-2045(13)70024-X. Epub 2013 Feb 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Binimetinib	Small molecule	45 mg	Oral
Subject	Binimetinib	Small molecule	60 mg	Oral

Indications

No indication recorded.